Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.09
+0.01 (0.21%)
Sep 2, 2026, 11:48 AM EDT - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Entrada Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $19. The average 1-year stock price forecast is 168.17% higher than the current stock price, while the lowest is $11 (+55.26%) and the highest is $25 (+252.86%).
Price Target: $19 (+168.17%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Entrada Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 7 | 7 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Buy Reiterates $10 → $11 | Buy | Reiterates | $10 → $11 | +55.26% | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 10, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 5, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +139.94% | Jun 5, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 | Buy | Reiterates | $23 | +224.63% | Jun 3, 2026 |
Financial Forecast
Revenue This Year
19.05M
from 25.42M
Decreased by -25.06%
Revenue Next Year
20.00M
from 19.05M
Increased by 4.99%
EPS This Year
-3.66
from -3.47
EPS Next Year
-3.14
from -3.66
EPS and Forward PE are based on non-GAAP adjusted numbers.